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Abstract
Background:  In prostate cancer, normal citrate-producing glandular secretory epithelial cells undergo a
metabolic transformation to malignant citrate-oxidizing cells. m-Aconitase is the critical step involved in this
altered citrate metabolism that is essential to prostate malignancy. The limiting m-aconitase activity in prostate
epithelial cells could be the result of a decreased level of m-aconitase enzyme and/or the inhibition of existing m-
aconitase. Earlier studies identified zinc as an inhibitor of m-aconitase activity in prostate cells; and that the
depletion of zinc in malignant cells is an important factor in this metabolic transformation. However, a possibility
remains that an altered expression and level of m-aconitase enzyme might also be involved in this metabolic
transformation. To address this issue, the in situ level of m-aconitase enzyme was determined by
immunohistochemical analysis of prostate cancer tissue sections and malignant prostate cell lines.
Results: The immunocytochemical procedure successfully identified the presence of m-aconitase localized in the
mitochondrial compartment in PC-3, LNCaP, and DU-145 malignant prostate cell lines. The examination of
prostate tissue sections from prostate cancer subjects demonstrated that m-aconitase enzyme is present in the
glandular epithelium of normal glands, hyperplastic glands, adenocrcinomatous glands, and prostatic intraepithelial
neoplastic foci. Quantitative analysis of the relative level of m-aconitase in the glandular epithelium of citrate-
producing adenomatous glands versus the citrate-oxidizing adenocarcinomatous glands revealed no significant
difference in m-aconitase enzyme levels. This is in contrast to the down-regulation of ZIP1 zinc transporter in the
malignant glands versus hyperplastic glands that exists in the same tissue samples.
Conclusion: The results demonstrate the existence of m-aconitase enzyme in the citrate-producing glandular
epithelial cells; so that deficient m-aconitase enzyme is not associated with the limiting m-aconitase activity that
prevents citrate oxidation in these cells. The level of m-aconitase is maintained in the malignant cells; so that an
altered enzyme level is not associated with the increased m-aconitase activity. Consequently, the elevated zinc
level that inhibits m-aconitase enzyme is responsible for the impaired citrate oxidation in normal and hyperplastic
prostate glandular epithelial cells. Moreover, the down-regulation of ZIP1 zinc transporter and corresponding
depletion of zinc results in the increase in the activity of the existing m-aconitase activity in the malignant prostate
cells. The studies now define the mechanism for the metabolic transformation that characterizes the essential
transition of normal citrate-producing epithelial cells to malignant citrate-oxidizing cells.
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Background
In prostate cancer (PCa), malignancy develops mainly
from the glandular epithelium of the prostate gland
peripheral zone. A major and persistent characteristic that
distinguishes normal prostate tissue from malignant pros-
tate tissue is the extraordinarily high citrate content of the
former versus the low citrate content of the latter [for
reviews see [1-4]]. The normal secretory epithelial cells
have the specialized function of production and secretion
of extraordinarily high levels of citrate. To achieve this
capability, these "citrate-producing" cells posses a unique
limiting m-aconitase enzyme activity that impairs citrate
oxidation. In malignant cells, m-aconitase activity is not
limiting and citrate oxidation is not impaired. This meta-
bolic transformation of normal citrate-producing cells to
citrate-oxidizing malignant cells is an essential event in
the development of prostate malignancy. Also, benign
prostatic hyperplasia (BPH) involves the proliferation of
citrate-producing glands. These are consistent relation-
ships that have been corroborated and established by in
situ magnetic resonance spectroscopy imaging of the
human prostate; which is now the most reliable proce-
dure for the identification and localization of malignant
loci in the prostate gland [for reviews see [4-6]]. Conse-
quently, it is essential to establish the mechanism of
impaired citrate oxidation in the normal secretory epithe-
lial cells, and the alteration of citrate production associ-
ated with the metabolic transformation in the malignant
cells.
In normal mammalian cell intermediary metabolism m-
aconitase typically exists in excess and is not a rate-limit-
ing or regulatory enzyme, and catalyzes the equilibrium
reaction:
~88 citrate ←→ 4 cis-aconitate ←→ ~8 isocitrate. 
This results in a characteristic citrate/isocitrate ratio ~10/1
for most mammalian tissues, regardless of the citrate con-
centration. In contrast, citrate-producing normal prostate
glands and hyperplastic glands exhibit a citrate/isocitrate
ratio ~30/1; which is indicative of a limiting m-aconitase
activity [1,7]. This is substantiated by the impaired citrate
oxidation but not isocitrate oxidation by citrate-accumu-
lating prostate cells [8,9]. A limited m-aconitase activity
could be the result of an inhibition of the enzyme and/or
a decrease in the level of the enzyme. Previous studies
established that the accumulation of high zinc levels,
which occurs in normal prostate cells [3,10,11], results in
the inhibition of m-aconitase activity and in a shift of its
equilibrium toward citrate [12,13]. In PCa, the malignant
prostate cells do not accumulate zinc, which leads to the
expectation that m-aconitase activity is not inhibited in
these cells and citrate oxidation occurs. In a recent study
involving measurements with prostate cancer tissue sec-
tions (14), we demonstrated that ZIP1 zinc transporter is
down-regulated and zinc levels are depleted in the glan-
dular epithelium of adenocarcinomatous glands. How-
ever, an alternative or additional consideration is the
possibility that the m-aconitase enzyme level might be
low in citrate-producing normal prostate cells, and/or the
enzyme might be over-expressed in malignant cells.
Therefore, it was important to determine the level of m-
aconitase enzyme in human prostate tissue samples and
compare its level in malignant and nonmalignant glands.
Moreover, this study was conducted with the same sam-
ples as in our previous report; so that the differences of
changes in ZIP1 levels can be contrasted with the present
results of m-aconitase levels. This report provides the first
identification of m-aconitase enzyme in malignant and
nonmalignant human prostate glandular epithelium.
Results
Costello et al [15] reported that the m-aconitase antibody
employed in this present study was specific for the mito-
chondrial isoform and was not reactive with cytosolic (c-)
aconitase. This conclusion was based on positive immu-
noreactivity (Western blots) with extracts of isolated mito-
chondrial preparations, and negative reactivity with
cytosolic extract preparations. However, for the present
immunohistochemistry studies, it was essential to estab-
lish that intra-mitochondrial m-aconitase could be
detected and that the antibody reaction was limited to the
mitochondria. To establish this, immunofluorescence
analysis was conducted with LNCaP cells in conjunction
with mitochondrial staining with Mitotracker. Figure 1
shows that the m-aconitase immunoreactivity was associ-
ated with and specific for the mitochondrial compart-
ment, and that the antibody is selective for the m-
aconitase isozyme.
We then proceeded to analyze human prostate tissue sec-
tions for m-aconitase immunoreactivity in malignant ver-
sus nonmalignant foci. Figure 2 presents the
representative immunohistochemical detection of m-aco-
nitase in BPH, malignant, normal, and PIN foci. The
results show that m-aconitase is present in the glandular
epithelium of all the glands regardless of the pathological
state. Also, the cellular level of m-aconitase is consistently
lower in stromal tissue than in glandular epithelium.
Most importantly, immunopositive detection of m-aconi-
tase is evident in the malignant glands as well as in the
normal glandular epithelium.
Table 1 is the summary of the immunohistochemical scor-
ing of m-aconitase reactivity of tissue sections from 22
cases of prostate cancer. The table presents the two param-
eters employed for quantitation of m-aconitase enzyme
level: the percent of cells within a gland that exhibited m-
aconitase immuno-positivity; and the cellular level of m-Molecular Cancer 2006, 5:14 http://www.molecular-cancer.com/content/5/1/14
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aconitase as represented by the m-aconitase-positive dots
(mitochondria) within the cells. In this study, we
restricted the analysis to the comparison of m-aconitase in
glands located in the same tissue section. One reason was
to eliminate, or at least minimize, any potential differ-
ences arising from the antibody diffusion into the cells
and into the mitochondria for immunoreactivity. Thus,
any comparative differences observed in the level of
immunoreactivity in the different glands of the same tis-
sue section would be due to comparative differences in
the level of m-aconitase.
It is apparent from Table 1 that m-aconitase immunoreac-
tivity is essentially the same for BPH glandular epithelium
and adenocarcinomatous glands. BPH glands, like normal
peripheral zone glands are citrate-producing glands;
whereas adenocarcinomatous glands are citrate-oxidizing
glands. Also, there is no correlation between the tumor
grade and m-aconitase immunoreactivity. This is consist-
ent with the fact that the decrease in citrate in malignant
cells occurs very early in malignancy and persists through
the progression of malignancy [4-6]. Although the
number of cases in which tissue samples that contained
normal glands and PIN (believed by many to be a precur-
sor stage of malignancy) was insufficient for statistical
analysis, these glands exhibited m-aconitase scoring simi-
lar to each other and similar to BPH and adenocarcinoma.
These results show that alteration in the level of m-aconi-
tase enzyme (i.e. altered m-aconitase expression/biosyn-
thesis) is not associated with the altered citrate oxidation
or production in malignant versus non-malignant cells.
This is in contrast to our earlier study [14] of changes in
the level of ZIP1 transporter in sections from the same tis-
sue samples employed in this current report. For compar-
ison, Table 1 shows those earlier results. The absence of a
change in m-aconitase enzyme level is evident in the same
glands that exhibit a marked down-regulation of the level
of ZIP1 transporter in malignant versus non-malignant
glands. Moreover, accompanying the down-regulation of
ZIP1 is a corresponding decrease in cellular zinc levels
[14]. Thus the absence of a demonstrable change in m-
aconitase enzyme level is not due to some artifact effect.
For additional corroboration of these results, we deter-
mined the expression of m-aconitase in LNCaP, DU-145,
and PC-3 malignant prostate cell lines and the effect of
zinc treatment on the level of m-aconitase in malignant
prostate cell lines. The results (figure 3) show that m-aco-
nitase is expressed in all the malignant cell lines. It is nota-
ble that the level of m-aconitase in untreated LNCaP cells
is higher than PC-3 cells although citrate oxidation by
LNCaP cells is negligible as compared to high citrate oxi-
dation by PC-3 cells [16,17]. This is due to the higher
accumulation of zinc in LNCaP cells that inhibits m-aco-
nitase activity [16]. Exposure of the cells to zinc had no
effect on the level of m-aconitase (figure 3). However, the
conditions employed results in cellular accumulation of
zinc (18, 19), which inhibits m-aconitase activity and cit-
rate oxidation. Therefore, these studies establish, for the
first time, that it is the accumulation of inhibitory levels of
zinc on m-aconitase activity, and not limiting levels of m-
aconitase enzyme, that prevents citrate-oxidation in pros-
tate cells.
Discussion
In typical mammalian cell metabolism, citrate is an essen-
tial intermediate for oxidation via the Krebs cycle and sub-
sequent ATP production from coupled phosphorylation.
Citrate must be converted to isocitrate by the action of m-
aconitase as the entry step for its oxidation via the Krebs
cycle. It is important in the intermediary energy metabo-
lism of mammalian cells that m-aconitase is not a limiting
reaction that would essentially truncate the Krebs cycle.
Therefore, the constituitive m-aconitase activity is typi-
Subcellular localization of m-aconitase Figure 1
Subcellular localization of m-aconitase. A-D. Immunofluorescent detection. LNCaP prostate cell line was probed with 
Mitotracker then fixed for immunofluorescence with Aconitase-2 Ab and visualized by Laser Scanning Confocal Microscope. A. 
no staining of either in nuclei (DAPI). B. red punctuate mitochondrial staining in cytoplasm (Mitotracker). C. green fluorescent 
of m-aconitase in cytoplasm (FITC). D. red and green fluorescence merge shows co-localization of m-aconitase in mitochon-
dria. E. Immunocytochemical detection of m-aconitase. Note the dark brown punctuate mitochondrial staining in cytoplasm; 
and well defined clear nucleus.Molecular Cancer 2006, 5:14 http://www.molecular-cancer.com/content/5/1/14
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cally in excess in mammalian cells, which insures an ade-
quate flux of citrate to isocitrate for oxidation as follows:
However, in normal prostate epithelial cells citrate is pre-
dominantly an end-product of intermediary metabolism,
rather than an utilizable intermediate as in most other
cells. It is well established that citrate-producing prostate
cells and their mitochondria readily oxidize isocitrate, but
not citrate [7-9,20]. These collective observations estab-
lish that the accumulation of citrate in citrate-producing
prostate cells is predominantly due to a limiting m-aconi-
tase activity (for additional supporting evidence see [1-
4,21]. Therefore, the possibility existed that the constitui-
tive level of m-aconitase enzyme in prostate cells might be
uniquely low and a contributing factor in the limited m-
aconitase activity. However, several studies with rat pros-
tate cells, pig prostate cells and human prostate cell lines
consistently demonstrated that the expression and level of
m-aconitase is not lower in citrate-producing cells as com-
ACCOA
OAA
CITRATE CIS ACON ISOCIT OXIDATION VIA
KREBS CYCLE
ACONITASE ACONITASE
Representative m-aconitase immunohistochemistry of human prostate tissue sections Figure 2
Representative m-aconitase immunohistochemistry of human prostate tissue sections. Left panel. A. Negative control. B. 
Field that shows adjacent BPH and malignant foci. C. Field showing adjacent PIN and malignant glands. Right panel. A-D are 
H&E staining; a-d are immunohistochemical staining. Note strong brown positive staining of glandular epithelium in all cases; 
and contrasting less staining of stroma.Molecular Cancer 2006, 5:14 http://www.molecular-cancer.com/content/5/1/14
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pared to that found in typical citrate-oxidizing cells
[15,22-24]. While this prostate m-aconitase relationship
has been established in animal studies and in cell culture
studies, the level of m-aconitase enzyme in human pros-
tate tissue had never been determined. The present studies
reveal that the constituitive level of m-aconitase is essen-
tially the same in BPH glandular epithelium and normal
peripheral zone glandular epithelium (both being citrate-
producing glands), and the adenocarcinomatous glands
(citrate-oxidizing glands) and PIN (presumed early malig-
nant stage).
The absence of an altered expression of m-aconitase is in
marked contrast with changes in the expression of ZIP1
zinc uptake transporter and in cellular zinc levels that we
recently reported [14]. The elimination of the involve-
ment of altered m-aconitase enzyme level leads to the
conclusion that the rate-limiting m-aconitase activity is
due to an inhibition of the enzyme. It is well established
that normal peripheral zone glands and BPH glands accu-
mulate extremely high zinc levels in association with their
unique ability to produce and accumulate extremely high
citrate levels; and that, in PCa, the malignant glands
exhibit a marked decrease in zinc levels and in citrate lev-
els [10,11]. These relationships are consistent with the
established effects of zinc in the inhibition of m-aconitase
activity and citrate oxidation [12,13], which permits the
unique peripheral zone glandular function (as in the pros-
tate of other animals) of net citrate production. In PCa,
the lost ability of the malignant cells to accumulate zinc
eliminates its inhibition of m-aconitase activity; and
thereby increases the oxidation of citrate and decreases the
cellular level of citrate.
Conclusion
The present study demonstrates the existence of similar
levels of m-aconitase enzyme in non-malignant citrate-
producing normal and BPH glandular epithelial cells as
Table 1: Aconitase immunoreactivity of BPH glandular epithelumversus adenocarcinomatous glands of prostate cancer tissue 
sections.
TUMOR ACONITASE IMMUNOREACTIVITY ZIP1 IMMUNOREACTIVITY
CASE # GRADE BPH PCA BPH Malignant
1 3 +++ 8.9 ++ 6.4 ++ Negative
2 3 + 6.4 +++ 11.0 ++ +
3 1 + 6.2 + 7.0 + Negative
4 2 +++ 14.6 +++ 12.2 + Negative
5 2 ++ 12.6 + 14.2 Negative Negative
6 1 +++ 12.2 +++ 16.6 ++ Negative
7 2 ++ 10.0 +++ 15.6 + +
8 1 +++ 11.4 ++ 8.3 ++ +
9 1 + 7.5 +++ 18.0 ++ Negative
10 2 + 8.4 + 8.6 ++ Negative
11 1 + 12.6 ++ 11.8 ++ Negative
12 2 + 9.7 +++ 15.8 Negative Negative
13 1 +++ 13.7 +++ 14.2 ++ +
14 1 +++ 13.9 +++ 14.5 + Negative
15 1 + 7.6 + 10.2 + Negative
16 1 ++ 11.6 +++ 13.9 + Negative
17 1 ++ 14.2 +++ 16.3 ++ +
18 1 ++ 9.2 ++ 10.0 + Negative
19 1 +++ 12.0 ++ 10.9 + Negative
20 2 +++ 14.7 +++ 18.2 ++ +
21 1 +++ 14.1 +++ 17.6 Negative Negative
22 3 +++ 16.3 +++ 17.9 ------------- -------------
t-TEST- MEAN(SE) 
POSITIVITY 2.1(0.85) 2.4(0.94)** 1.68(0.23) 0.32(0.10)*
QUANTITATION 11.3(2.9) 13. 1(3.8)** ------------- -------------
Scoring of immunoreactivity: Negative, no positive cells;
score +, <10% positive cells; score ++, 10–50% positive cells;
score +++, > 50% positive cells.
Quantitation = Average number of well defined ACON IHC dots per cell.
Mean Positivity = sum of +'s/22
ZIP1 data taken from Franklin et al [14].
BPH vs Malignant *P < 0.01; **no significant differenceMolecular Cancer 2006, 5:14 http://www.molecular-cancer.com/content/5/1/14
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compared to the citrate-oxidizing malignant cells. Conse-
quently, the limiting m-aconitase activity of the citrate-
producing epithelial cells is not the result of a deficient
level of the enzyme (reaction 1); and the increased m-aco-
nitase activity of citrate-oxidizing cells is not the result of
an elevated level of the enzyme (reaction 2), as follows:
These results, in concert with previous reports, establish
the mechanism of the regulation of m-aconitase and cit-
rate oxidation in normal human prostate glandular epi-
thelial cells and in the metabolic transformation in the
malignant cells. The inhibitory effect of elevated zinc lev-
els on m-aconitase activity is responsible for the impaired
citrate oxidation by normal and BPH citrate-producing
prostate cell (reaction 1). The lost ability of the malignant
cells to accumulate zinc removes the inhibition of existing
m-aconitase so that citrate oxidation occurs (reaction 2).
This elucidation of the mechanism associated with the
metabolic transformation to citrate oxidation provides
the bioenergetic and synthetic requirements that are
essential for the manifestation of the malignant process of
the prostate neoplastic cell. Thus, important insight into
the genetic/metabolic relationships of the pathogenesis
and progression of prostate cancer is now evolving, which
will provide new approaches to its detection and treat-
ment.
Methods
Human prostate tissue
Twenty-two cases of prostatic adenocarcinoma slides were
obtained from RPCI that contained both adenocarcino-
matous foci and adjacent benign prostatic hyperplasia.
Four of the cases contained normal prostatic glands and
six cases contained prostatic intra-epithelial neoplastic
foci (PIN). One section of normal and another BPH were
obtained from the Cooperative Human Tissue Network of
the National Cancer Institute, National Institutes of
Health, Bethesda, MD. The slides were coded without
identification related to the patients. Institutional Review
Board approval was obtained.
Immunohistochemistry
Immunohistochemistry was performed with the m-aconi-
tase antibody (1:500 dilution) developed and described
by Costello et al [15]. The immunohistochemistry proto-
col is described by Desouki and Rowan [25]. Briefly, the
slides were de-parafinized by incubation in xylene and
ascending grades of alcohol. Antigen retrieval was done by
heating in 10 mM sodium citrate buffer (pH 6.0) @ 98°C,
incubated in 1% hydrogen peroxide, blocked with 10%
goat serum with avidin D (Vector Laboratories, Burlin-
game, CA), incubated with m-aconitase antibody in 10%
goat serum with biotin at 4°C over night followed by
incubation with secondary peroxidase labeled anti-rabbit
IgG (H+L) antibody (Vector Laboratories, Burlingame,
CA) in a concentration of 5 ug/ml. Color was developed
by incubating slides with DAB kit (Vector Laboratories,
Burlingame, CA) followed by counterstaining with Hema-
toxylin. One section from each prostatic tissue was stained
with H&E for histological characterization of lesions and
grading of tumors by a pathologist (M.M.D), according to
the World Health Organization grading system [26].
Grade 1 is defined by well-differentiated glands with min-
imal anaplasia in which the nuclei are almost uniform
with minimal variation in size and shape and few detect-
able nucleoli. Grade 2 is defined by moderately differenti-
ated glands with moderate nuclear anaplasia with many
nucleoli. Grade 3 is defined by poorly differentiated or
undifferentiated glands showing marked anaplasia in
which the nuclei showed marked variation in size and
irregular shapes, vesicular, with marked abnormal mitotic
figures. All sections were examined with light E600 Nikon
microscope. The pictures were processed with Spot soft-
ware, version 4.1, Diagnostic Instruments, Inc (Sterling
Heights, MI).
Immunofluorescence localization of m-aconitase
LNCaP cells (human prostate cancer cell line) were grown
on cover-slips and maintained in RPMI media with
glutamine (Gibco, Grand Island, NY) supplemented with
10% FBS + 100 U/ml penicillin and 100 ug/ml streptomy-
cin + 20 ng/ml EGF for immunofluorescence. The sub-cel-
lular localization of m-aconitase in relation to
mitochondria was determined by the combination of
immunofluorescence with m-aconitase and the
MitoTracker Red CMXRos selective probe (Molecular
Probes, Eugene, OR). LNCaP cells were grown on the lam-
inin-coated glass cover slips in tissue culture plates until
reaching about 75% confluence. The immunofluores-
cence protocol described by Makino et al [27] was
ACCOA
(1)
OAA
CITRATE CIS ACON ISOCIT OXIDATION VIA
KREBS CYCLE
ACONITASE
ZN
ACONITASE
ACCOA
(2)
OAA
CITRATE CIS ACON ISOCIT OXIDATION VIA
KREBS CYCLE
ACONITASE ACONITASE
Western blot analysis of m-aconitase levels in human pros- tate cancer cell lines Figure 3
Western blot analysis of m-aconitase levels in human pros-
tate cancer cell lines. The cells were exposed for 24 hours to 
medium supplemented with 15 uM zinc and to unsupple-
mented medium.Molecular Cancer 2006, 5:14 http://www.molecular-cancer.com/content/5/1/14
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employed with modification. The cells were incubated in
media containing 100 nM MitoTracker for 30 minutes at
37°C. The medium was then replaced with fresh media
without MitoTracker and incubated for 15 minutes at
37°C. Fixation of the cells was done in freshly prepared
media containing 4% paraformaldehyde for 15 minutes
at 37°C. Permeabilization was performed with 0.2 % Tri-
ton-x100 in PBS for 5 minutes at room temp and blocking
with 1% BSA in PBS for 1 hour at room temperature. The
cells were washed with PBS and incubated with m-aconi-
tase antibody for 60 minutes at room temperature; and
followed by incubation with secondary anti-rabbit IgG-
FITC (Covance Research Products, Inc. Denver, PA) in 1%
BSA for 60 minutes (1:1000 dilution). Mounting with
Vectashield with DAPI mounting media (Vector Laborato-
ries, Burlingame, CA) was done before sealing with glass
slides. Microscopic examination with Leica SP2 Laser
Scanning Confocal Microscope was carried out. Emissions
were; Blue Diole Laser 405, Argon Laser 488 and Helum/
Neon Laser 543 for DAPI (blue), FITC (green) and
MitoTracker (red), respectively.
Evaluation of m-aconitase immunoreactivity
The m-aconitase enzyme level was determined by the
immunohistochemistry scoring method of Desouki and
Rowan [25]. Two criteria were employed: the percent of
epithelial cells within the glands that exhibit m-aconitase
immunopositivity; and the number of immunopositive
cytoplasmic dots (aconitase-detected mitochondria)
within the epithelial cells. The cells with punctuate cyto-
plasmic dots were considered positive for m-aconitase.
Twenty to fifty randomized high power fields (oil immer-
sion, x100) in a section from each case were evaluated.
The scores employed were; negative, no positive cells,
score +, <10% positive; score ++, 10–50% positive; score
+++, > 50% positive. For quantifying the m-aconitase
within the epithelial cells, the average number of identifi-
able well-defined m-aconitase immunopositive dots per
cell was determined by oil immersion high power field
(x100) examination of 50 cells. The Excel program was
used to calculate the correlation between tumor grades
and aconitase immunopositivity scores. A t-test was also
conducted for statistical comparison of m-aconitase levels
in BPH glands versus adenocarcinomatous glands.
Western blot analysis of m-aconitase
The level of m-aconitase in the malignant prostate cell
lines was determined by Western blot analysis of cell
extracts as previously described [15].
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